The development and application of decellularized extracellular matrices (ECM) has grown rapidly in the fields of cell biology, tissue engineering and regenerative medicine in recent years. Similar to decellularized tissues and whole organs, cell-derived matrices (CDMs) represent bioactive, biocompatible materials consisting of a complex assembly of fibrillar proteins, matrix macromolecules and associated growth factors that often recapitulate, at least to some extent, the composition and organization of native ECM microenvironments. The unique ability to engineer CDMs de novo based on cell source and culture methods makes them an attractive alternative to conventional allogeneic and xenogeneic tissue-derived matrices that are currently harvested from cadaveric sources, suffer from inherent heterogeneity, and have limited ability for customization. Although
Introduction
The extracellular matrix (ECM) of tissues is a complex, highly organized assembly of macromolecules and incorporated signalling factors. In addition to providing tissue structure and a substrate for cell adhesion, the ECM also contributes cues for cell migration, proliferation, differentiation and survival, which are essential processes in development, homeostasis and tissue repair. The primary constituents of the ECM include fibrillar proteins (e.g. collagens, fibronectin, laminin), glycosaminoglycans (GAGs; e.g. heparan sulphate, chondroitin sulphate, hyaluronan), proteoglycans (e.g. decorin, versican, aggrecan) and matricellular proteins (e.g. osteopontin, thrombospondin). As well as contributing directly to the overall structural and mechanical properties of tissue, ECM components are also involved in the binding, sequestration and stabilization of signalling molecules incorporated within the matrix.
The composition and distribution of specific matrix components varies with the type of tissue, and can also be altered by the tissue's developmental stage and/or pathological state.
Biomaterials used in tissue engineering and regenerative medicine attempt to recapitulate the multifactorial aspects of ECM function, however synthetic materials and matrices formed from isolated biological materials, such as collagen, fibrin or hyaluronan, fail to achieve the molecular complexity and organization of native tissue matrices. This has motivated the use of native ECM itself as a biomaterial source. ECM derived from allogenic or xenogenic tissues, reviewed in-depth elsewhere [1] [2] [3] , has emerged as an increasingly common source of natural biomaterials. Decellularized or devitalized skin, small intestinal submucosa, urinary bladder matrix, amniotic membrane, ligaments, blood vessels and heart valves are but a few examples of tissue ECM used in pre-clinical research and clinical therapies. The use of whole organ decellularization is also of interest for tissue engineering applications due to the preserved tissue architecture [4] [5] [6] [7] .
However, naturally derived matrices are inherently limited in their capacity for manipulation beyond processing procedures and tissue source, and possess uncontrolled variability that may arise from the age, health and gender of individual sources.
ECM derived from cultured mammalian cells provides an alternative to native tissuederived ECM. Cell-derived matrices (CDM) contain a complex yet organized mixture of macromolecules that can mimic aspects of native tissue microenvironments. In contrast to tissue-derived matrices, CDM have greater ability for customization by selecting the type(s) of cells used to generate the ECM, the culture system (e.g. 2D versus 3D culture; static versus perfusion), the application of external stimuli to modulate ECM production and also the ability to genetically modify the source cells to augment or silence the expression of target molecules. CDM can also be used to confer bioactivity to synthetic scaffolds through the deposition of matrix molecules on the scaffold surface. The tradeoff with respect to tissue-derived matrices is that CDM typically have poorer mechanical
properties, making them unsuitable for certain applications. However, mechanical preconditioning applied prior to decellularization has been shown to significantly improve the mechanical properties of CDM, particularly for cardiovascular applications 8, 9 .
The purpose of this review is to explore the current uses of cell-derived matrices in tissue engineering, stem cell therapies and other biomedical applications, and discuss their current successes, limitations and future directions. CDM have been used in a variety of applications, including as coatings for synthetic scaffolds, biomimetic microenvironments for stem cell differentiation, and decellularized tissue engineered heart valves and vascular grafts. While several results are promising, there remains a fair amount of variability in the reported effects CDM have in vitro and in vivo, likely due to many differences in the cells, methods and applications examined thus far. Throughout this review we will attempt to identify key factors, such as cell source(s), processing techniques and experimental designs, that may help to explain these inconsistencies and provide insights into the best practices for the derivation and application of CDM in biomedical engineering.
Overview of Cell-derived Matrices Fabrication
Generating cell-derived matrices involves three major considerations: cell source, culture method and processing method. 20 . Within the context of this review, the term cellderived matrices (CDM) is used to describe any non-living cell-generated matrix, regardless of the specific processing method.
Cell-derived matrices in skeletal tissue engineering
Orthopaedic tissue engineering and regenerative strategies aim to improve upon current clinical practices for repairing large bone defects and damaged cartilage. Cell-derived matrices are being investigated (i) as a scaffold coating to improve the biological activity and tissue integration of synthetic scaffolds for regenerative therapies and (ii) as alternative cell culture substrates for maintaining, expanding and differentiating stem cells, and primary chondrocytes and osteoblasts for future use in orthopaedic cell therapies.
The effect of CDM on MSC osteogenic differentiation has been extensively studied in vitro [21] [22] [23] [24] [25] [26] [27] . MSCs cultured on titanium (Ti) fibre meshes and poly(e-caprolactone) (PCL) microfibre scaffolds coated with previously deposited osMSC-synthesized matrix exhibited enhanced osteogenic differentiation, characterized by increased alkaline phosphatase (ALP) activity and calcium deposition, relative to MSCs cultured on unmodified Ti and PCL scaffolds [21] [22] [23] [24] . Furthermore, MSCs cultured on Ti/ECM scaffolds upregulated expression of a subset of osteogenic genes (alkaline phosphatase, osteopontin, osteocalcin, osteonectin, osteomodulin and parathyroid hormone receptor) and decreased expression of aggrecan, a protein associated with chondrogenesis 27 . The MSC-derived matrices also supported increased mineralization, even in the absence of dexamethasone, a common osteogenic additive. However, increased calcium deposition appeared to be primarily due to mineralization of the pre-existing matrix as the acellular construct exhibited only slightly less calcium deposition than PCL/ECM construct with MSC 24 .
While the ECM/scaffolds did not appear to be able to induce osteogenic differentiation in naïve MSC, they were capable of maintaining osteogenic differentiation of MSC without dexamethasone if MSCs had already been primed towards the osteogenic lineage prior to being seeded on the scaffold [22] [23] [24] . The ability to maintain osteogenic differentiation of primed MSC has important implications for promoting osteogenesis in vivo in the absence of exogenous soluble factor stimulation.
Decellularized matrices derived from fibroblasts and pre-osteoblasts yielded similar MSC osteogenic differentiation on composite poly(lactic-co-glycolic acid; PLGA)/hydroxyapatite(HA)/β-tricalcium(β-TCP) scaffolds 28 . The CDM-coated composite scaffolds contained fibronectin and collage type I, and stimulated increased ALP activity and mineralization when reseeded with MSC in osteogenic media, compared to uncoated PLGA/HA/β-TCP scaffolds 28 . Decaris et al. demonstrated that osteogenic CDM generated as 2D culture substrates could be coated onto a 3D scaffold, while retaining their capacity to modulate osteogenic differentiation 29, 30 . MSC-derived matrices deposited TCPS culture dishes were decellularized using Triton X-100, NH 4 OH and DNAse, then homogenized in acetic acid and deposited as a matrix solution on 3D macroporous poly(lactide-co-glycolide; PLG) scaffolds 29, 30 . The transferred matrix maintained the ability to enhance osteogenic differentiation of MSC in the presence of β-glycerophosphate (β-GP) and dexamethasone, demonstrated by increased expression of osteogenic markers and ALP activity 29, 30 . The retention of bioactivity by the transferred CDM implies that composition of the matrix, and not necessarily the matrix structure, is sufficient to enhance a cellular response. However, as discussed further below, these positive in vitro outcomes did not accurately predict in vivo responses.
Cell-derived matrices for bone regeneration and osteogenesis have been evaluated in ectopic and orthotopic sites in vivo. Subcutaneous implants of polyesterurethane scaffolds coated with mineralized osMSC-derived ECM induced the ingrowth of host cells and the formation of a mineralized matrix that stained positive for bone sialoprotein (BSP), whereas no mineralization or BSP was found in the uncoated polymer scaffold explants 31 .
Similarly, Hong et al. demonstrated enhanced osteogenic differentiation of naïve MSCs
implanted on PLGA/HA/β-TCP scaffolds coated with fibroblast-CDM using a subcutaneous ectopic bone formation model 28 . Explanted matrix-coated scaffolds had greater collagen and calcium deposition and ALP expression than uncoated scaffolds 28 .
The increased osteogenic differentiation of implanted MSCs was attributed primarily to considering the increase in vessel density was observed with and without the inclusion of viable MSC in the scaffolds 26, 29 . In both cases, the lack of bone formation may be attributed to reduced or altered osteoinductive properties of the matrices due to processing methods. In the first study, the matrix was transferred from a 2D culture plate and coated onto a scaffold. While previous in vitro studies indicated that the bioactivity of the matrix was preserved, it is possible that the homogenization in acetic acid affected the in vivo response. In the second study, the matrix was sterilized with ethylene oxide (EtO) following decellularization using freeze-thaw cycles since in vitro studies suggested that CDM retained its bioactivity following EtO sterilization 21 . However, EtO sterilization of demineralized bone matrix is still debated due to evidence that the doses required to sterilize the products reduces their osteoinductivity, specifically when high temperatures are used 34 .
Cell-derived matrices rich in collagen and GAGs have also been used to enhance the chondrogenic differentiation of MSCs and synovium-derived stem cells (SDSCs) for cartilage regeneration. In vitro chondrogenesis of MSC is typically induced by supplementation with transforming growth factor β (TGF-β), dexamethasone and ascorbate-2-phosphate 35, 36 . Differentiating MSCs on chondrocyte-derived matrices instead of uncoated PCL scaffolds moderately enhanced the GAG deposition and GAG synthetic activity (GAG/DNA per scaffold) in the presence of TGF-β1 25 and decreased the expression of collagen I in the absence of TGF-β1. However, the gene expression of aggrecan, collagen II and collagen I was not affected by the presence of the ECM in TGF-β1 treated cultures. Furthermore, this effect was TGF-β dependent, as the matrix alone was not sufficient to induce chondrogenesis 25 . In the reverse scenario, in vitro culture of chondrocytes on MSC-derived matrices had increased collagen type II and aggrecan expression in the presence of chondrogenic media 37 , but this improvement was only observed when the matrices were derived from MSCs cultured in a basic growth medium and not chondrogenic medium containing TGF-β3 and dexamethasone.
Unfortunately, in vitro culture on either MSC-derived matrix did not rescue the phenotype of chondrocytes obtained from an osteoarthritic donor 37 .
SDSCs cultured on decellularized SDSC matrix (DSCM) had improved proliferation and attenuated oxidative stress-induced senescence during culture in vitro 14, 38 . SDSC expanded on DSCM also had enhanced chondrogenic potential but impaired differentiation along adipogenic and osteogenic lineages, compared to SDSC expanded on tissue culture polystyrene (TCPS) 14, 38 . The benefit of culturing the SDSC on DSCM was retained after the cells were removed from the matrix and cultured as pellets 14, 38 or injected into a cartilage defect in vivo 39 . DSCM-expanded SDSC pellets underwent striking chondrogenic differentiation in response to TGF-β1 and TGF-β3 in vitro, characterized by increased size, intensified staining for collagen type II, sulphated GAGs and decreased collagen type I staining compared to TCPS-expanded SDSC pellets 39 .
Intra-articular injection of DSCM-expanded SDSC improved the repair of partialthickness cartilage defects in pigs 39 . Upon explant at 3 months, the defect area and newly formed tissue in the group treated with DSCM-expanded cells stained more intensely for GAGs and collagen type II, and less collagen type I compared to defects treated with TCPS-expanded SDSC 39 .
In a direct therapeutic application of CDM, Li et al. developed a membrane composed of layered decellularized chondrocyte-derived ECM to improve the outcome of bone marrow stimulation in a canine model 40 . The thin, flexible membrane, composed primarily of collagen and sulphated GAGs, was applied to cover a cartilage defect and protect the bone marrow stem cell-containing blot clot that resulted from bone marrow stimulation. Coverage with the decellularized membrane resulted in more cartilage-like tissue formed within the defect by 18 weeks than uncovered defects 40 .
CDM have successfully been applied in in vitro osteogenic and chondrogenic differentiation schemes, but thus far they have had limited success in improving regenerative skeletal therapies in vivo. For the most part, the CDM in these applications were used as a coating for metallic and polymeric scaffolds. It is possible that the osteogenic or chondrogenic cues within the CDM lack the potency required to drive an in vivo response or that the bulk scaffold effects remain dominant in the in vivo environment.
Another possibility is the lifespan of the CDM, which would likely be remodelled over the span of weeks, could be much shorter than the time scale required for bone or cartilage defect repair, thus limiting the impact of the transiently present CDM. In the case of cell-seeded scaffolds, retention of viable cells within the scaffold continues to be a limitation due to hypoxic cell death or migration of cells away from the scaffold 29 that may interfere with properly evaluating CDM in vivo.
Cell-derived matrices in cardiovascular tissue engineering
In contrast to skeletal engineering, CDMs in cardiovascular engineering applications tend to be used as regenerative therapies, where the CDM itself is used to replace damaged or diseased vessels and valves, rather than as a scaffold coating or cell culture substrate. The shortage of human allogenic heart valves and autogenic or allogenic vascular grafts for cardiovascular therapy has motivated the used of decellularized xenogenic and allogenic valves and vascular grafts. However, the limited availability of cadaveric allogenic tissues and potential risk(s) associated with xenogenic tissue sources has prompted significant research into the development of tissue engineered blood vessels (TEBV) and tissue engineered heart valves (TEHV). old male patient who required vascular access for hemodialysis 41 . During the first 8 weeks, the graft remained patent with a stable 5 mm diameter, however no reports have been released to date regarding the performance of the graft following puncture for hemodialysis access. With this approach, the patient wait time to prepare the devitalized graft with a viable, autologous endothelium and conduct quality control testing was less then 2 weeks 41 . In a follow-up case study, allogenic devitalized TEBVs prepared without the endothelial layer were implanted as brachial-axillary arteriovenous shunts for hemodialysis access in three patients 20 . Grafts were used for hemodialysis access as early as 7 weeks post-implantation, and functioned without signs of aneurysms for up to 11 months; however, two of the three patients did require interventions to maintain graft patency. The authors noted that the decellularized graft, similar to synthetic grafts, did bleed slightly into the surrounding tissue at previous puncture sites whereas previously tested living, autologous TEVG did not. An interesting observation was that lymphotoxic cross-reactivity and panel reactive antibody tests indicated that the allogenic grafts were well-tolerated and did not elicit an immune response despite the fact the grafts were simply dehydrated instead of decellularized using detergents and DNase treatments 20 .
Using a similar approach, Niklason and collaborators also developed a TEBV using human smooth muscle cells cultured on a tubular biodegradable polyglycolic acid (PGA) scaffold for 8 weeks, at which point the PGA scaffolds had mostly degraded and the constructs were decellularized 8 . In vitro mechanical testing indicated that the decellularized grafts possessed similar burst strength and suture retention as a human saphenous vein 8 . Furthermore, the decellularized grafts had an 80% patency rate over six weeks in an arterial graft model in nude rats, despite lacking any endothelial lining prior to implantation 43 . Histological analysis did reveal that host endothelial cells (von CDMs have also been used to construct tissue engineered heart valves. In this application, human vascular fibroblasts 50 , human neonatal dermal fibroblasts 51 and ovine fibroblasts [52] [53] [54] have been seeded in fibrin carriers on degradable synthetic templates and cultured 4- macrophages), respectively, may be detrimental to the long-term functioning of the engineered tissue. Residual stresses from TEHV being cultured in a closed position have also been suggested as a contributing factor to valve retraction 50 . In contrast, decellularized human native heart valves exhibited limited recellularization and maintained good coaptation without regurgitation over the duration of the study.
Culturing the matrix producing fibroblasts with TGF-β1 to stimulate the deposition of elastin may help preserve the leaflet geometry 56 . 62 . Matrices generated by mouse embryonic fibroblasts (MEF), human umbilical vein endothelial cells (HUVEC) and human neonatal dermal fibroblasts (nFb) were compared to matrices generated by human MSCs grown in osteogenic factors (osteoECM) or ascorbic acid (aaECM). The matrices were deposited on a fibronectin (FN) layer covalently bonded to the TCPS to prevent the delamination of the matrix, which is a common problem with matrices simply physisorbed onto surfaces. Once decellularized, all the matrices were characterized as having a complex fibrillar structure, with tethered GAG aggregates within the network.
The MSC-ECM was thicker than the other matrices, and also had an elasticity that Human and mouse embryonic stem cells (ESCs) are of great interest for regenerative medicine due to their capacity to differentiate into all somatic cell types [64] [65] [66] [67] . 57 .
Pellet cultures of dedifferentiated chondrocytes expanded on CDM for 2 passages also contained more GAGs, stronger peripheral staining of collagen type II and were larger in size compared to pellets formed from TCPS-expanded chondrocytes 57 . Similar studies conducted using SDSC-derived matrix with primary pig chondrocytes 11 , and chondrocyte-derived matrix with primary bovine chondrocytes 12, 72 have also demonstrated delayed chondrocyte dedifferentiation when cultured on CDM substrate.
As noted earlier, an important consideration in the use of CDM is that the composition and quality of the matrix is dependent on the source cell population. For example, aging has been shown to have a profound effect on the quality of matrices that MSCs deposit 59 .
Matrix derived from BMCs isolated from young mice (3 month old) improved the proliferation and osteogenic potential of MSC from aged mice (18 months old) to a level comparable with young MSC, and reduced intracellular reactive oxygen species 59 . In comparison, both young and aged MSC grown on aged MSC-derived matrix had significant impairment of proliferation and osteogenesis. These results suggest that matrices derived from young MSC can rejuvenate aged MSC populations and contributes to maintaining healthy MSC function. Confocal Raman microscopic analysis of the young and old MSC-derived matrices suggested that the old matrix contained more mineralized phosphate, while the young ECM appeared to contain more collagens, indicating that aging impacts the composition of MSC-derived matrix 59 . This study has far reaching implications for MSC biology and regenerative medicine, as it suggests that culture on matrix derived from young MSCs may improve the quality and quantity of MSC isolated from aged patients for regenerative cell therapies.
Just as disease states are often reflected by cell phenotypes, the native ECM of disease tissues and tumours can also have distinct features that may contribute to or result from a disease state 73 . Studying the composition and properties of matrices derived from diseased cell populations may enable researchers to identify and better understand the relationship between cells and matrix in disease propagation, and enable the development of superior disease models for basic research. Reichert et al. used matrices produced by human osteoblasts to develop an in vitro model of bone metastasis, which recapitulated features of prostate cancer bone metastasis, including loss of epithelial phenotype 74 . Also, the role of ECM in craniosynostosis (CS), the premature fusion of cranial sutures, was investigated using decellularized matrix produced by osteoblasts from patients with CS and healthy individuals 75 . Previous studies had detected decreased expression of TGF-β, a protein involved in regulating bone resorption 76 , in MSCs harvested from fused versus unfused sutures in mice 77 . TGF-β had significantly reduced binding affinity for ECM secreted by CS osteoblasts, compared to osteoblasts from healthy individuals, indicating that differences in the ECM of patients with CS likely contribute to the pathogenesis of the disease 75 .
Embryonic stem cell-derived matrices
In most cases, cell-derived matrices are used to recapitulate the microenvironment of adult tissues and the cells used to derive the matrix are sourced directly from the tissue of interest. However, there are instances, as noted above, when adult matrices may be limited in their ability to promote a desired behaviour, such as tissue regeneration. For example, scarring and impaired wound healing are significant clinical challenges related to traumatic and surgical wounds, and co-morbidities of diseases like diabetes. The main matrix components in skin are collagens, elastin, GAGs, laminin, nidogen and fibronectin 78 , and matrices derived from fibroblasts, the primary cell type within the dermis, recapitulate some the main components in adult skin 10, 57, 79 . Acellular dermal matrix allografts and skin substitutes, such as INTEGRA ® Dermal Regeneration
Template, are routinely used in the clinic to treat burns and chronic wounds [80] [81] [82] [83] . However, adult skin is also known to have reduced regenerative capability compared to fetal skin.
At early stages of development, fetal skin can undergo scarless healing and is rich in matrix proteins, GAGs and growth factors that have are known to promote wound repair [84] [85] [86] . Therefore, instead of recapitulating adult skin matrix, a matrix reflecting the protein composition of fetal tissue may provide a better therapeutic material for promoting scarless wound healing. 87 . An interesting trend in the expression profile was that while many matrix proteins had constant or decreased expression initially, the expression for many matrix-associated proteins started to increase expression by day 10. Similarly, the EBs were also shown to express genes of many therapeutically relevant secreted morphogens, including bone morphogenic proteins (BMPs), FGFs, TGFs, platelet-derived growth factors (PDGFs) and VEGFs, some of which would be retained within the EB matrix 87 . The presence of versican and hyaluronan within the EB matrix was independently confirmed in a separate study 88 . The rich and complex nature of the EB matrix, particularly at later time points, led us to postulate that the EB matrix (EBM) and its associated growth factors may provide a therapeutic platform for delivering embryonic-like matrices and paracrine factors to damaged tissues and organs, such as skin and bone. Successful decellularization of EBs has been achieved using both chemical and mechanical methods, matrix components are retained, and the EBM can support exogenous cell attachment and proliferation [89] [90] [91] .
Similar to the use of MSC-derived matrices to improve somatic stem cell expansion, Goh et al. proposed that ESC-derived ECM be used to recapitulate the embryonic microenvironment to improve the efficiency of current ESC lineage-specific differentiation protocols 92 . Two distinct EBM were generated by culturing mESC EBs with or without retinoic acid (RA), an inducer of neural differentiation. Prior to decellularization, both RA-treated and untreated EBs contained collagen I, collagen IV, fibronectin and laminin, although staining for collagen I, collagen IV and laminin staining appeared to be more intense in the spontaneously differentiating EBs than the RA-EBM and the distribution pattern of fibronectin differed between the two groups.
While the expression of these four proteins was retained following the decellularization process, the total protein content and sulphated GAG content was significantly reduced in both groups. Total collagen and sulphated GAG content remained higher in the EBM generated from spontaneously differentiating EBs ( This study demonstrated that EB-derived matrices can support ESC proliferation and differentiation, and that the differentiation protocol used to obtain the EBM can influence the phenotype of reseeded ESCs. Furthermore, it suggests that the use of an appropriate ESC matrix may improve soluble factor-directed differentiation. 
Future directions
The use of cell derived matrices as bulk biomaterials, scaffold coatings and cell culture substrates has permeated the field of regenerative medicine. This review sought to highlight the current status of CDM across various applications and identify some of the successes and major challenges that remain. CDM offer promising alternative biomaterials as decellularization and sterilization techniques are optimized and appropriate cell sources and culture conditions are identified for producing more potent and instructive materials.
As the use of CDM has become more established, one can foresee the potential for engineering matrices with desired properties using genetically engineered cells, small molecules or other soluble factors to induce overexpression of specific matrix
components. An example would be inducing overexpression of elastin 95 by fibroblasts generating the TEHV and TEBV matrix in an effort to reduce leaflet retraction or to improve the elasticity and resilience, respectively. As the cellular components of these transgenic cells would be removed prior to in vivo applications, the risk typically associated with transgenic, immortalized or tumorigenic cell lines would be eliminated. There are a number of limitations and challenges that would need to be addressed to ensure complete decellularization and limit undesirable effects, such as the release of proinflammatory factors in response to the stimuli. However, decellularization by intentional activation of programmed cell death is an intriguing proposal that warrants further investigation.
Summary
Cell-derived matrices offer an alternative to tissue-derived matrices and have been used Figure 1 . Common culture methods for generating cell-derived matrices (CDM). CDMs can be generated using a variety of culture methods that offer flexibility and tunability to the desired applications. When grown in monolayers, adherent cells deposit a thin layer of matrix molecules upon the underlying surface.
For thicker CDM constructs, cells can be embedded in a degradable carrier scaffold. Over time, the degradable scaffold is replaced by ECM deposited by the embedded cells, which yields a three-dimensional ECM construct following decellularization. Culturing cells as multicellular aggregates also produces threedimensional matrices, without the need for a carrier scaffold. However, individual aggregates tend to be much smaller than the thick constructs obtained when using a carrier scaffold. Similar to monolayer cultures, cells can also be cultured on the surface of synthetic scaffolds. The deposited matrix molecules remain on the scaffold surface following decellularization, and can improve the bioactivity and biocompatibility of the synthetic material. 120x74mm (300 x 300 DPI)
